Entering text into the input field will update the search result below

Biohaven says pivotal study for intranasal migraine therapy met main goals

Dec. 06, 2021 9:33 AM ETBiohaven Ltd. (BHVN)By: Dulan Lokuwithana, SA News Editor

Headache-conceptual artwork-3d illustration

peterschreiber.media/iStock via Getty Images

  • Announcing topline data from its second pivotal trial for intranasal migraine therapy, zavegepant, Biohaven Pharmaceutical (NYSE:BHVN) said that its Phase 3 study met the co-primary regulatory endpoints.
  • In the 1,405-patient trial, CGRP receptor antagonist has indicated

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.